Niemann-Pick Disease and Gaucher Disease: 10 Key Facts on Two New FDA Approvals

Two rare disease approvals in November 2026: adrabetadex (Lembaz), the first treatment shown to improve survival in infantile-onset Niemann-Pick disease type C, and venglustat (Infilbray) for neurological type 3 Gaucher disease.

·

·

8–12 minutes

·

Edited by Joshua Adebanjo, RN

Niemann-Pick and Gaucher: Two New Treatments

Families affected by two rare inherited conditions, Niemann-Pick disease type C and type 3 Gaucher disease, have new treatment options after the US Food and Drug Administration (FDA) approved adrabetadex (Lembaz) and venglustat (Infilbray) this week.

Adrabetadex, approved on 17 November 2026, is the first medicine shown to improve survival in people with Niemann-Pick disease type C (NPC) whose neurological symptoms began before age six. In the evidence reviewed by the FDA, median survival was 8.5 years with treatment compared with 4.9 years in matched untreated patients. Venglustat, approved on 18 November, is the first treatment for the neurological symptoms of type 3 Gaucher disease. Both are lysosomal storage disorders, in which fatty substances build up inside cells, including in the brain.

Niemann-Pick disease

Imagine the parents of a four-year-old girl who once ran and chattered like other children. Over the past year, she has become unsteady, struggles to swallow, and has started losing words. After many tests, she is diagnosed with Niemann-Pick disease type C, a rare inherited condition. Her parents are told there has been no treatment proven to help children like her live longer. Now, with a new approval, her care team discusses a treatment given into the fluid around the spine every two weeks, along with careful hearing checks. It’s not a cure, but for her family, the chance of more time together means everything.

What happened

On 17 November 2026, the FDA approved adrabetadex (Lembaz), marketed by Beren Therapeutics, to reduce the risk of death in adults and children weighing at least 7 kg who have Niemann-Pick disease type C with neurological symptoms starting before age six.

On 18 November 2026, the FDA approved venglustat (Infilbray), from Sanofi, for neurological manifestations of type 3 Gaucher disease (GD3) in adults and children weighing at least 15 kg.

Both medicines received approval based on studies in small numbers of patients, which is common for rare diseases. Adrabetadex received Breakthrough Therapy designation and a priority review voucher.

10 key facts

  1. The FDA approved adrabetadex (Lembaz) for Niemann-Pick disease type C on 17 November 2026.
  2. It is the first NPC medicine shown to improve survival.
  3. Median survival was 8.5 years with treatment vs 4.9 years without.
  4. Adrabetadex is given into the spinal fluid every two weeks.
  5. It carries a boxed warning for hearing loss.
  6. The FDA approved venglustat (Infilbray) for type 3 Gaucher disease on 18 November.
  7. Venglustat is a pill that crosses into the brain.
  8. It is the first treatment for neurological symptoms of GD3.
  9. Both are inherited lysosomal storage disorders.
  10. Niemann-Pick disease type C affects about 1 in 150,000 people.

The numbers at a glance

  • Adrabetadex approval: 17 November 2026
  • 36 treated patients compared with matched controls
  • Median survival: 8.5 vs 4.9 years (55% lower risk of death)
  • Given intrathecally every 2 weeks
  • NPC: about 1 in 150,000 people
  • Venglustat approval: 18 November 2026
  • LEAP2MONO trial: 43 patients aged 12+
  • Venglustat for patients weighing at least 15 kg

What are Niemann-Pick disease type C and Gaucher disease?

Niemann-Pick disease type C is an inherited condition caused by changes in the NPC1 or NPC2 genes. These disrupt how cholesterol and other fats are moved inside cells, causing them to build up, especially in the brain. Symptoms can include unsteadiness, swallowing problems, slurred speech, difficulty moving the eyes up and down, seizures and loss of skills. When symptoms begin in early childhood, the disease often progresses quickly.

Gaucher disease is caused by a lack of the enzyme glucocerebrosidase, leading to a build-up of fatty substances called glycosphingolipids. Type 1 mainly affects the spleen, liver, blood and bones. Type 3 also affects the brain, causing problems with eye movements, balance, coordination, speech, memory and thinking.

Both conditions are inherited in an autosomal recessive pattern, meaning a child must inherit a faulty gene from each parent.

Why this matters

Until now, no treatment had been shown to help children with severe Niemann-Pick disease type C live longer. Existing medicines, arimoclomol and levacetylleucine, are approved for older or heavier patients but have not shown a survival benefit.

For type 3 Gaucher disease, enzyme replacement therapy treats the body but cannot cross into the brain. Venglustat, a pill that reaches the brain, offers the first option to target neurological symptoms directly.

Rare disease approvals bring hope to small communities of families who often face long diagnostic journeys and few treatments.

What officials and experts said

Dr Elizabeth M. Berry-Kravis, lead investigator for the adrabetadex expanded access programme, said: ‘As the only NPC medicine to improve survival, LEMBAZ gives children more time to be children.’

Professor Pramod Mistry, director of the Yale Lysosomal Disease Center, said venglustat’s approval ‘represents a major milestone for patients, families, and the global Type 3 Gaucher disease community’.

What this means for you

  • Families affected by NPC or GD3 should ask their specialist team whether these treatments are suitable.
  • Genetic counselling can explain inheritance and testing for other family members.
  • For adrabetadex, regular hearing tests are required.
  • For venglustat, report mood changes or thoughts of self-harm promptly.
  • Connect with patient organisations for support and information.
  • Ask about clinical trials and access programmes in your country.

What this means for nurses and health workers

Specialist nurses coordinate complex care for families living with rare lysosomal diseases.

  • Support families through diagnosis and treatment decisions.
  • Coordinate intrathecal treatments and hearing assessments.
  • Monitor for side effects such as ataxia and fatigue.
  • Support swallowing, nutrition and mobility.
  • Link families with genetic counselling.
  • Provide emotional and practical support.

The global picture

Rare diseases affect an estimated 300 million people worldwide, but most have no approved treatment. Access to new rare disease medicines varies widely between countries, and costs can be very high.

Adrabetadex safety

Adrabetadex carries a boxed warning for hearing impairment, including permanent hearing loss ranging from mild to profound, which occurred in some patients with normal hearing at the start. Hearing tests are required before treatment and 1 to 2 weeks after each dose. Unsteadiness (ataxia) and tiredness can occur within days of dosing, sometimes requiring hospital care. Other common side effects include vomiting, back pain, headache, fever, diarrhoea, nausea and cough.

How adrabetadex works

Adrabetadex is based on a sugar-like molecule called 2-hydroxypropyl-beta-cyclodextrin, which is thought to free cholesterol trapped inside nerve cells. Because it doesn’t easily cross from the blood into the brain, it is injected into the spinal fluid (intrathecally) by a trained provider.

Venglustat trial and safety

In the LEAP2MONO trial, 43 patients aged 12 and older received venglustat or the intravenous enzyme imiglucerase for 52 weeks. Venglustat performed better on a combined measure of balance, coordination and thinking. Side effects included diarrhoea, enlarged spleen, nausea, depression, gastroenteritis and vomiting. The label warns about suicidal thoughts and behaviour, clouding of the eye lens in children, and harm to an unborn baby.

Living with a rare disease

Families often face isolation, long journeys to specialist centres and uncertainty. Patient organisations, online communities and specialist nurses can provide support, information and connection.

Newborn and family screening

Early diagnosis allows earlier treatment. Relatives of affected children may be offered genetic testing.

What ‘rare’ means

A rare disease is usually defined as affecting fewer than 1 in 2,000 people. Many are genetic and begin in childhood.

Children with Niemann-Pick disease often see many specialists, so a single coordinating nurse or key worker can make care much easier for families.

Hope with realism

New approvals for rare diseases are important milestones, but they rarely offer a cure. Adrabetadex improved survival in the evidence reviewed but did not stop the disease, and it carries serious side effects that require careful monitoring. Venglustat improved a combined measure of neurological function in a relatively small trial, and longer-term effects are still being studied. Families can find it helpful to discuss realistic goals with their care team, including quality of life, comfort, communication and time together. Palliative care teams can work alongside specialist treatment from diagnosis, supporting symptom control and family wellbeing. Connecting with other families through patient organisations can provide practical tips and emotional strength.

Myths and facts

Myth: Rare diseases are too rare to research.
Fact: New treatments are being developed and approved.

Myth: These conditions are caused by something parents did.
Fact: They are inherited through genes.

Myth: A new medicine is a cure.
Fact: Both treatments slow or improve symptoms but don’t cure the diseases.

Myth: Enzyme therapy treats brain symptoms in Gaucher type 3.
Fact: It doesn’t cross into the brain; venglustat does.

Questions and answers

What is adrabetadex used for?

Severe infantile-onset Niemann-Pick disease type C.

How is it given?

Into the spinal fluid every two weeks.

What is the main risk?

Hearing loss.

What is venglustat used for?

Neurological symptoms of type 3 Gaucher disease.

How is venglustat taken?

As a pill by mouth.

Are these diseases inherited?

Yes, usually from both parents.

Are the treatments available outside the US?

That depends on approvals in other countries.

What happens next

Regulators in other countries may review the medicines, and longer-term data will show how lasting their benefits are. Patient groups are expected to campaign for access. We will report further developments.

Key takeaways

  • The FDA approved adrabetadex (Lembaz) for Niemann-Pick disease type C on 17 November 2026.
  • Median survival was 8.5 years with treatment vs 4.9 years without.
  • It carries a boxed warning for hearing loss.
  • Venglustat is a pill that crosses into the brain.
  • Both are inherited lysosomal storage disorders.
  • Niemann-Pick disease type C affects about 1 in 150,000 people.

How we report health news

Nursing Media Network reports health news using official sources such as the World Health Organization, national public health agencies, medicines regulators and peer-reviewed research, which are linked at the end of each story. Figures in fast-moving stories, such as outbreaks, change quickly, so we state the date each number refers to. If you are reading this later, check the latest update from the official source before making decisions.

News reports describe what has happened across a population. They cannot tell you what is right for your own health. If a story raises questions about your treatment, symptoms or risk, speak to your nurse or healthcare provider before making any changes.

Staying informed without feeling overwhelmed

A constant stream of health headlines can leave people anxious or confused. It can help to choose one or two trusted sources and check them at set times, rather than scrolling throughout the day. Focus on what you can control, such as vaccinations, regular check-ups, healthy routines and knowing when to seek care. Talk about worries with family, friends or your nurse rather than keeping them to yourself, and take a break from news if it is affecting your sleep or mood. Being informed is useful; being overwhelmed is not.

Finding reliable health information

Health information online varies widely in quality. Prefer sources such as the World Health Organization, national health ministries, public health agencies, university hospitals and registered professional bodies. Be cautious with social media posts, miracle cures and products sold with promises that sound too good to be true.

If you read something that worries you or contradicts the advice you have been given, write it down and discuss it with your nurse or healthcare provider. They can explain how it applies to your own situation and help you separate evidence from rumour.

Questions to ask your nurse or healthcare provider

  • Is my child eligible for adrabetadex?
  • How often will hearing be tested?
  • Would venglustat help with neurological symptoms?
  • What side effects should we watch for?
  • Should other family members be tested?
  • Where can we find support groups?

But if these diseases are so rare, why does this news matter?

For affected families, a first effective treatment can mean more time and better quality of life, and each approval advances rare disease research.

Your next step: If your family is affected by NPC or Gaucher disease, ask your specialist team about these new treatments and genetic counselling.

Related: Genetic conditions · Hearing loss · Seizures

Sources: NeurologyLive: adrabetadex; NeurologyLive: venglustat; FDA: novel drug approvals 2026.

Joshua Ibukunoluwa Adebanjo

Founder & Editor-in-Chief

Joshua Ibukunoluwa Adebanjo

RN, RM, RPHN, BNSc (Obafemi Awolowo University)

Joshua is a registered nurse, midwife and public health nurse with clinical experience at Obafemi Awolowo University Teaching Hospitals Complex. He founded Nursing Media Network to give nurses worldwide trustworthy news, career guidance and a stronger public voice, and leads its editorial direction.

Full profile · Editorial policy · joshuadebanjo.com

Health information on Nursing Media Network is for education and does not replace advice from your own nurse or healthcare provider.

Leave a Reply

Most read

Discover more from Nursing Media Network

Subscribe now to keep reading and get access to the full archive.

Continue reading